1
|
Cavenago M, Serianni G, Baltador C, Barbisan M, De Muri M, Pimazzoni A, Poggi C, Veltri P, Aprile D, Antoni V, Armelao L, Baseggio L, Candeloro V, Cervaro V, Franchin L, Jain P, Laterza B, Maniero M, Martini D, Minarello A, Pasqualotto R, Rancan M, Ravarotto D, Recchia M, Sartori E, Sattin M, Ugoletti M, Variale V, Zucchetti S. Experimental experience and improvement of NIO1 H− ion source. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.01.071] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Pavei M, Marcuzzi D, Zaccaria P, Agostinetti P, Aprile D, Barzon A, Baseggio L, Bernardi M, Bigi M, Boldrin M, Brombin M, Cervaro V, Chitarin G, Dal Bello S, Degli Agostini F, Fasolo D, Franchin L, Gambetta G, Garbuglia A, Geli F, Graceffa J, Grando L, Laterza B, Masiello A, Pasqualotto R, Recchia M, Rizzolo A, Rossetto F, Serianni G, Sottocornola A, Spolaore M, Tiso A, Toigo V, Tollin M, Zamengo A, Zanotto L. Spider beam source ready for operation. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.01.067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
3
|
Baseggio L, Debliquis A, Jacob M, Bouyer S, Bennani H, Chapuis N, Garnache Ottou F, Genevieve F, Guy J, Harrivel V, Letestu R, Mayeur-Rousse C, Drenou B. MULTICENTRIC MFI30 STUDY: STANDARDIZATION OF CD30 EXPRESSION BY FLOW CYTOMETRY IN NON-HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.23_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- L. Baseggio
- Laboratoire d'Hématologie; Hospice Civils de Lyon/Groupement Hospitalier SUD; Pierre Benite France
| | - A. Debliquis
- Laboratoire Hématologie; Groupe Hospitalier de la Région Mulhouse Sud Alsace (GHRMSA); Mulhouse France
| | - M. Jacob
- Laboratoire Immunologie; CHU Grenoble; Grenoble France
| | - S. Bouyer
- Laboratoire de Biologie; CHU Poitiers; Poitiers France
| | - H. Bennani
- Laboratoire de Biologie; Hôpital Foch; Suresnes France
| | - N. Chapuis
- Laboratoire Hématologie; APHP-Cochin; Paris France
| | | | - F. Genevieve
- Laboratoire Hématologie/Institut de Biologie/Cytométrie en Flux; CH Angers; Angers France
| | - J. Guy
- Laboratoire Hématologie/Plateforme de Cytométrie; CHU-Dijon; Dijon France
| | - V. Harrivel
- Centre de Biologie Humaine; CHU Amiens; Amiens France
| | - R. Letestu
- Laboratoire Hématologie; APHP-Avicenne; Bobigny France
| | | | - B. Drenou
- Laboratoire Hématologie; Groupe Hospitalier de la Région Mulhouse Sud Alsace (GHRMSA); Mulhouse France
| |
Collapse
|
4
|
Bommier C, Mauduit C, Fontaine J, Bourbon E, Sujobert P, Huet S, Baseggio L, Hayette S, Laurent C, Bachy E, Ghesquières H, Salles G, Traverse-Glehen A. ONE-YEAR REAL-LIFE TARGETED NEXT GENERATION SEQUENCING FOR LYMPHOMA DIAGNOSIS: STUDY OF PATIENTS FROM THE FRENCH LYMPHOMA NETWORK IN RHÔNE-ALPES. Hematol Oncol 2019. [DOI: 10.1002/hon.2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C. Bommier
- Haematology Department; Assistance Publique - Hôpitaux de Paris; Paris France
| | - C. Mauduit
- Pathology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | - J. Fontaine
- Pathology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | - E. Bourbon
- Pathology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Sujobert
- Laboratory of Haematology; Hospices Civils de Lyon; Pierre-Bénite France
| | - S. Huet
- Laboratory of Haematology; Hospices Civils de Lyon; Pierre-Bénite France
| | - L. Baseggio
- Laboratory of Haematology; Hospices Civils de Lyon; Pierre-Bénite France
| | - S. Hayette
- Laboratory of Haematology; Hospices Civils de Lyon; Pierre-Bénite France
| | - C. Laurent
- Pathology Department; Institut Universitaire du Cancer - Oncopôle; Toulouse France
| | - E. Bachy
- Haematology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | - H. Ghesquières
- Haematology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | - G. Salles
- Haematology Department; Hospices Civils de Lyon; Pierre-Bénite France
| | | |
Collapse
|
5
|
Mollaret E, Gomez E, Nadel B, Naiglin L, Anquetin M, Barau C, Baseggio L, Bret C, Brisou G, Brousset P, Camara-Clayette V, Cartron G, Da Cunha K, Dartigues P, Dupuis J, Ghaleh B, Gravelle P, Houot R, Karmous-Gadacha O, Laurent C, Moreaux J, Pangault C, Ribrag V, Salles G, Szablewski V, Thouault V, Uze G, Verge V, Ysebaert L, Gaulard P, Fest T. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Mollaret
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - E. Gomez
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - B. Nadel
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - L. Naiglin
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - M. Anquetin
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Barau
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - L. Baseggio
- Laboratoire d'Hématologie; Groupement Hospitalier Sud/Hospices Civils de Lyon; Pierre-Bénite France
| | - C. Bret
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - G. Brisou
- Hématologie Clinique; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Brousset
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - V. Camara-Clayette
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | - K. Da Cunha
- CRB Sud; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Dartigues
- Département de Biologie et Pathologie Médicales - Service de pathologie Morphologique; Gustave Roussy; Villejuif France
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - B. Ghaleh
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - P. Gravelle
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - R. Houot
- Hématologie; CHU Rennes - Pontchaillou; RENNES France
| | | | - C. Laurent
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - J. Moreaux
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - C. Pangault
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| | - V. Ribrag
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Salles
- Hématologie Clinique; Hospices Civils de Lyon / Université Claude Bernard; Pierre Bénite France
| | - V. Szablewski
- Pathologie et Oncobiologie; CHU Montpellier; Montpellier France
| | - V. Thouault
- Laboratoire d'hématologie; CHU Rennes - Pontchaillou; Rennes France
| | - G. Uze
- UMR 5235; CNRS / University Montpellier; Montpellier France
| | - V. Verge
- Département de Biologie et Pathologie Médicales - Laboratoire d'hématologie; Gustave Roussy; Villejuif France
| | - L. Ysebaert
- Hématologie; IUC-Toulouse Oncopole; Toulouse France
| | - P. Gaulard
- Department of Pathology; AP-HP; Créteil France
| | - T. Fest
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| |
Collapse
|
6
|
Ferrero S, Ladetto M, Beldjord K, Drandi D, Stelitano C, Bernard S, Castagnari B, Bouabdallah K, Cesaretti M, Alvarez I, Gressin R, Ponzoni M, Tripodo C, Traverse-Glehen A, Baseggio L, Liberati A, Merli M, Tessoulin B, Patti C, Cabras M, Feugier P, Pozzi S, Zucca E, Iannitto E, Thieblemont C. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.39_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - M. Ladetto
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo; SC Ematologia; Alessandria Italy
| | - K. Beldjord
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - D. Drandi
- Hematology Division; Università di Torino, Molecular Biotechnologies and Health Sciences; Torino Italy
| | - C. Stelitano
- U.O.C. Ematologia; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - S. Bernard
- Hemato-Oncology; Hôpital Saint-Louis; Paris France
| | - B. Castagnari
- UOC of Hematology; Hospital Santa Maria delle Croci; Ravenna Italy
| | | | - M. Cesaretti
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - I. Alvarez
- AUSL Reggio Emilia/IRCCS; Arcispedale Santa Maria Nuova, UOC of Hematology; Reggio Emilia Italy
| | - R. Gressin
- Grenoble Alpes University Hospital; Department of Hematology; Grenoble France
| | - M. Ponzoni
- Pathology Unit; Ateneo Vita-Salute and San Raffaele Scientific Institute; Milano Italy
| | - C. Tripodo
- Department of Health Science; Human Pathology Section,Tumor Immunology Unit, University of Palermo; Palermo Italy
| | | | - L. Baseggio
- Pierre-Benite; Cytology, CHU Lyon; Lyon France
| | - A. Liberati
- University of Perugia; Oncology-Hematology, Santa Maria Hospital; Terni Italy
| | - M. Merli
- ASST Settelaghi; University Hospital Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | | | - C. Patti
- Division of Hematology; Azienda Ospedali Riuniti Villa Sofia-Cervello; Palermo Italy
| | - M. Cabras
- Ospedale Businco; Division of Hematology; Cagliari Italy
| | - P. Feugier
- University Hospital of Nancy; Department of Haematology; Nancy France
| | - S. Pozzi
- Unit of Target Therapy in Onco-Hematology and Osteoncology, University of Modena and Reggio Emilia, Department of Oncology and Hematology; Modena Cancer Center; Modena Italy
| | - E. Zucca
- Institute of Oncology Research; Università della Svizzera Italiana (USI), IOSI, Oncology Institute of Southern Switzerland and IOR; Bellinzona Switzerland
| | - E. Iannitto
- Department of Oncology; “La Maddalena”, Onco-Hematology and BMT Unit; Palermo Italy
| | | |
Collapse
|
7
|
Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, Salles G, Baseggio L. Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol 2018; 40:e59-e62. [DOI: 10.1111/ijlh.12824] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 03/08/2018] [Indexed: 11/28/2022]
Affiliation(s)
- R. Favre
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
| | - D. Manzoni
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
| | - A. Traverse-Glehen
- Department of Anatomic Pathology; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - A. Verney
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - L. Jallades
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - E. Callet-Bauchu
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - P. Sujobert
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| | - G. Salles
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
- Department of Clinic Hematology; Hospices Civils De Lyon/GHS; Lyon France
| | - L. Baseggio
- Department of Hematologic Laboratory; Hospices Civils De Lyon/GHS; Lyon France
- Cancer Research Center of Lyon; INSERM 1052-CNRS UMR5286 « Clinical and Experimental Models of Lymphomagenesis »; Lyon France
| |
Collapse
|
8
|
Cavenago M, Serianni G, De Muri M, Agostinetti P, Antoni V, Baltador C, Barbisan M, Baseggio L, Bigi M, Cervaro V, Degli Agostini F, Fagotti E, Kulevoy T, Ippolito N, Laterza B, Minarello A, Maniero M, Pasqualotto R, Petrenko S, Poggi M, Ravarotto D, Recchia M, Sartori E, Sattin M, Sonato P, Taccogna F, Variale V, Veltri P, Zaniol B, Zanotto L, Zucchetti S. First experiments with the negative ion source NIO1. Rev Sci Instrum 2016; 87:02B320. [PMID: 26932048 DOI: 10.1063/1.4932616] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Neutral Beam Injectors (NBIs), which need to be strongly optimized in the perspective of DEMO reactor, request a thorough understanding of the negative ion source used and of the multi-beamlet optics. A relatively compact radio frequency (rf) ion source, named NIO1 (Negative Ion Optimization 1), with 9 beam apertures for a total H(-) current of 130 mA, 60 kV acceleration voltage, was installed at Consorzio RFX, including a high voltage deck and an X-ray shield, to provide a test bench for source optimizations for activities in support to the ITER NBI test facility. NIO1 status and plasma experiments both with air and with hydrogen as filling gas are described. Transition from a weak plasma to an inductively coupled plasma is clearly evident for the former gas and may be triggered by rising the rf power (over 0.5 kW) at low pressure (equal or below 2 Pa). Transition in hydrogen plasma requires more rf power (over 1.5 kW).
Collapse
Affiliation(s)
- M Cavenago
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - G Serianni
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - M De Muri
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - P Agostinetti
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - V Antoni
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - C Baltador
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - M Barbisan
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - L Baseggio
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - M Bigi
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - V Cervaro
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | | | - E Fagotti
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - T Kulevoy
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - N Ippolito
- Istituto Nazionale di Fisica Nucleare, Bari, Italy
| | - B Laterza
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - A Minarello
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - M Maniero
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - R Pasqualotto
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - S Petrenko
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - M Poggi
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - D Ravarotto
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - M Recchia
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - E Sartori
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - M Sattin
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro PD, Italy
| | - P Sonato
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - F Taccogna
- Istituto Nazionale di Fisica Nucleare, Bari, Italy
| | - V Variale
- Istituto Nazionale di Fisica Nucleare, Bari, Italy
| | - P Veltri
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - B Zaniol
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - L Zanotto
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| | - S Zucchetti
- Consorzio RFX, Corso Stati Uniti 4, I-35127 Padova, Italy
| |
Collapse
|
9
|
Miguet L, Lennon S, Baseggio L, Traverse-Glehen A, Berger F, Perrusson N, Chenard MP, Galoisy AC, Eischen A, Mayeur-Rousse C, Maar A, Fornecker L, Herbrecht R, Felman P, Van Dorsselaer A, Carapito C, Cianférani S, Mauvieux L. Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia 2013; 27:1748-50. [PMID: 23302770 DOI: 10.1038/leu.2013.3] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
10
|
Chhuy J, Morel D, Goeddert G, Magaud JP, Felman P, Baseggio L. Pertinence of the Sysmex XE-5000™ parameters: rule of slide review in a context of ‘normal’ lymphocyte count (defined from control and mantle cell lymphoma blood specimens). Int J Lab Hematol 2012; 35:510-6. [DOI: 10.1111/ijlh.12042] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2012] [Accepted: 11/13/2012] [Indexed: 11/30/2022]
Affiliation(s)
- J. Chhuy
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
| | - D. Morel
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
- UMR5239 Pathologies des cellules lymphoïdes; Université Claude Bernard; Lyon France
| | - G. Goeddert
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
| | - J.-P. Magaud
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
- UMR5239 Pathologies des cellules lymphoïdes; Université Claude Bernard; Lyon France
| | - P. Felman
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
- UMR5239 Pathologies des cellules lymphoïdes; Université Claude Bernard; Lyon France
| | - L. Baseggio
- Service d'Hématologie Biologique; Centre Hospitalier Lyon-Sud; Hospices Civils de Lyon; Pierre Bénite France
- UMR5239 Pathologies des cellules lymphoïdes; Université Claude Bernard; Lyon France
| |
Collapse
|
11
|
Baseggio L, Traverse-Glehen A, Callet-Bauchu E, Morel D, Magaud JP, Berger F, Salles G, Felman P. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). Hematol Oncol 2011; 29:47-51. [PMID: 20677173 DOI: 10.1002/hon.957] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
'Splenic red pulp lymphoma with numerous basophilic villous lymphocytes' (SRPL), recently described, is characterized by clinical, morphologic, immunologic, cytogenetic and molecular features distinct from SMZL/SLVL and HCL. In particular, the intensity of CD11c staining (expressed as fluorescence intensity -RFI-) in SRPL is significantly different from the RFI in SMZL/SLVL and HCL. Moreover the use of a scoring system based on the expression of CD11c, CD22, CD76, CD38 and CD27 appears to improve the differential diagnosis between SRPL and SMZL/SLVL and emphasizes that SRPL is an entity closed to but distinct from SMZL/SLVL.
Collapse
Affiliation(s)
- L Baseggio
- Laboratoire d'Hématologie cellulaire, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Traverse-Glehen A, Verney A, Baseggio L, Felman P, Callet-Bauchu E, Thieblemont C, Ffrench M, Magaud JP, Coiffier B, Berger F, Salles G. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia 2007; 21:1821-4. [PMID: 17476282 DOI: 10.1038/sj.leu.2404706] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
13
|
Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 48:162-73. [PMID: 16405665 DOI: 10.1111/j.1365-2559.2005.02309.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
AIMS To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL). NMZL is a recently characterized lymphoma and few series have been published. METHODS AND RESULTS The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%). Other features included peripheral blood involvement (23%), anaemia (24%), thrombocytopenia (10%) and presence of serum M component (33%), while the previously reported association with hepatitis C virus and cryoglobulinaemia was not found. Relapses were frequent but the majority of patients receiving chemotherapy had a good initial response. Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL). Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%). Plasmacytoid or plasmacytic differentiation was a very common feature (61%). Large cells and a high mitotic count were also frequent (57%). CONCLUSION NMZL can be distinguished from splenic MZL and extranodal MZL by its aggressive morphology and disseminated disease at presentation.
Collapse
Affiliation(s)
- A Traverse-Glehen
- Service d'Anatomie Pathologique, Centre Hospitalier Lyon Sud, Pierre Benite, Lyon, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Baseggio L, Berger F, Morel D, Delfau-Larue MH, Goedert G, Salles G, Magaud JP, Felman P. Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia 2005; 20:296-303. [PMID: 16341050 DOI: 10.1038/sj.leu.2404013] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis. In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data. According to previous results, a fraction of T cells expressed CD10 in 10/11 lymph nodes. Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node. In contrast, in all control samples (100), none CD10-positive T cell was identified. This is to our knowledge the first description of circulating CD10 neoplastic T cells in AITL. Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.
Collapse
Affiliation(s)
- L Baseggio
- Laboratoire d'Hématologie cellulaire, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Callet-Bauchu E, Baseggio L, Felman P, Traverse-Glehen A, Berger F, Morel D, Gazzo S, Poncet C, Thieblemont C, Coiffier B, Magaud JP, Salles G. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 2005; 19:1818-23. [PMID: 16094418 DOI: 10.1038/sj.leu.2403909] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The purpose of this study was to document the frequency and distribution of karyotypic changes present at diagnosis in 103 non-MALT marginal zone cell lymphoma (MZL) patients. This cytogenetic analysis of a large cohort extends previous observations and allows the identification of new cytogenetic features. Abnormalities identified in more than 15% of patients included +3/+3q (37%), 7q deletions (31%), +18/+18q (28%), 6q deletions (19%), +12/+12q (15%) and 8p deletions (15%). Trisomy 3/3q, 7q deletions, +18 and +12 were seen in different combinations in more than 30% of patients in comparison to 2% in lymphocytic lymphomas/chronic lymphocytic leukemias, 1% in mantle cell lymphomas and 7% in follicular lymphomas. The marked propensity of these abnormalities to be recurrently associated with the same tumoral clone of individual karyotypes allowed the delineation of a cytogenetic profile that may help to distinguish non-MALT MZL among other mature B-cell neoplasms. If +3/3q, +12/+12q, and 6q, 7q and 8p deletions were significantly associated with clinical prognostic factors previously reported to influence survival and time to progression, patients displaying these abnormalities did not experience a significantly shorter time to progression.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Chromosome Aberrations
- Cohort Studies
- Cytogenetic Analysis
- Disease Progression
- Female
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Lymphoma, B-Cell/classification
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell, Marginal Zone/classification
- Lymphoma, B-Cell, Marginal Zone/diagnosis
- Lymphoma, B-Cell, Marginal Zone/genetics
- Lymphoma, Follicular/diagnosis
- Lymphoma, Follicular/genetics
- Lymphoma, Mantle-Cell/diagnosis
- Lymphoma, Mantle-Cell/genetics
- Male
- Middle Aged
- Time Factors
Collapse
Affiliation(s)
- E Callet-Bauchu
- Service d'Hématologie Biologique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. ACTA ACUST UNITED AC 2004; 31:15-9. [PMID: 15009176 DOI: 10.1111/j.1365-2370.2004.00440.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Single nucleotide polymorphisms in the tumour necrosis factor alpha (TNF-alpha) promoter region may modulate TNF-alpha gene transcriptional activity by modifying the binding of transcription factors. Here we confirm that a specific DNA complex binds preferentially the variant TNF2 allele in various cell types and demonstrate that activating protein (AP)-2, myeloid zinc finger gene 1 (MZF-1) and Sp1 are not involved in this complex.
Collapse
Affiliation(s)
- L Baseggio
- Equipe d'Accueil 3737 Pathologie des Cellules Lymphoïdes, Claude Bernard University, Lyon, France
| | | | | | | | | | | |
Collapse
|
17
|
Thieblemont C, Chettab K, Felman P, Callet-Bauchu E, Traverse-Glehen A, Berger F, Dumontet C, Cerutti C, Baseggio L, Salles G, Paultre C, Coiffier B, McGregor JL. Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia 2002; 16:2326-9. [PMID: 12399979 DOI: 10.1038/sj.leu.2402691] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2002] [Accepted: 06/05/2002] [Indexed: 11/09/2022]
MESH Headings
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Cell Physiological Phenomena
- DNA, Neoplasm/analysis
- Diagnosis, Differential
- Gene Expression Profiling
- Humans
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/metabolism
- Lymphoma, Mantle-Cell/diagnosis
- Lymphoma, Mantle-Cell/genetics
- Lymphoma, Mantle-Cell/metabolism
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Oligonucleotide Array Sequence Analysis
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
|
18
|
Baseggio L, Charlot C, Picollet J, Bienvenu J, Salles G. High circulating tumor necrosis factor levels correlate with increased evels of soluble CD14 in patients with non-Hodgkin's lymphoma. Haematologica 2001; 86:774-5. [PMID: 11454540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
|
19
|
Baseggio L, Bienvenu J, Charlot C, Picollet J, Felman P, Coiffier B, Salles G. Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from non-Hodgkin's lymphoma patients. Exp Hematol 2001; 29:330-8. [PMID: 11274761 DOI: 10.1016/s0301-472x(00)00672-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
OBJECTIVE The aim of the present study was to investigate the capacity of normal immune blood cells from non-Hodgkin's lymphoma patients to produce tumor necrosis factor (TNF) after lipopolysaccharide (LPS) stimulation and the influence of the TNF (-308) polymorphism in this production. MATERIALS AND METHODS A whole peripheral blood cell assay was utilized following LPS stimulation. At selected incubation times, supernatants were harvested for protein dosage, while mRNA was extracted and reverse-transcribed. The amount of TNF mRNA was quantified using real-time quantitative polymerase chain reaction (PCR) and genomic DNA was typed for TNF (-308) polymorphism. RESULTS Upon LPS stimulation, TNF-secreted protein was slightly but not significantly increased in lymphoma patients when compared to controls. In contrast, the relative TNF mRNA amounts were significantly higher in lymphoma patients at 30 minutes (median 27.75 vs. 16.00; Mann-Whitney U-test p < 0.05), at 4 hours (52.00 vs. 31.00; p < 0.05), and at 24 hours (19.50 vs. 9.00; p < 0.05). In addition, patients carrying the variant TNF2 allele had higher relative TNF mRNA levels than TNF1 homozygotes (p = 0.02). CONCLUSION The LPS-induced TNF mRNA levels are higher in peripheral blood cells (PBC) from lymphoma patients than from controls, while TNF protein secretion is not strikingly different. Altered regulation of TNF mRNA translation or TNF protein secretion may contribute to these observations. Taken together, an increased susceptibility for TNF gene transcription after LPS stimulation was observed in PBC (mainly in monocytes) from lymphoma patients, and especially those carrying the TNF2 allele.
Collapse
Affiliation(s)
- L Baseggio
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | | | | | | | | | | | | |
Collapse
|
20
|
Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950-6. [PMID: 10706860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
Marginal zone B-cell lymphoma (MZL) is a recently individualized lymphoma that encompasses mucosa-associated lymphoid tissue (MALT) lymphoma, splenic lymphoma with or without villous lymphocytes, and nodal lymphoma with or without monocytoid B-cells. If the clinical description and outcome of MALT lymphoma is well known, this is not the case for the other subtypes. We reviewed 124 patients presenting non-MALT MZL treated in our department to describe the morphologic and clinical presentation and the outcome of these lymphomas. Four clinical subtypes were observed: splenic, 59 patients; nodal, 37 patients; disseminated (splenic and nodal), 20 patients; and leukemic (not splenic nor nodal), 8 patients. These lymphomas were usually CD5-, CD10-, CD23-, and CD43-, but the detection of one or, rarely, two of these antigens may be observed. Bone marrow and blood infiltrations were frequent, except in the nodal subtype, but these locations were not associated with a poorer outcome. Splenic and leukemic subtypes were associated with a median time to progression (TTP) longer than 5 years, even in the absence of treatment or of complete response to therapy. Nodal and disseminated subtypes were associated with a median TTP of 1 year. However, in all these subtypes, survival was good with a median survival of 9 years, allowing these lymphomas to be classified as indolent. Because of the retrospective nature of this analysis, no conclusion may be drawn on the therapeutic aspects, but conservative treatments seem recommended for leukemic and splenic subtypes. (Blood. 2000;95:1950-1956)
Collapse
MESH Headings
- Age Factors
- Disease Progression
- Female
- Flow Cytometry
- Humans
- Karyotyping
- Lymphatic Metastasis
- Lymphoma, B-Cell/classification
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/mortality
- Lymphoma, B-Cell/pathology
- Lymphoma, B-Cell, Marginal Zone/classification
- Lymphoma, B-Cell, Marginal Zone/diagnosis
- Lymphoma, B-Cell, Marginal Zone/pathology
- Male
- Middle Aged
- Splenic Neoplasms/secondary
- Time Factors
- Treatment Outcome
Collapse
Affiliation(s)
- F Berger
- Service d'Anatomie Pathologique and Laboratoire d'Hèmatologie, Hùpital Edouard-Herriot, Lyon, France
| | | | | | | | | | | | | | | | | |
Collapse
|